What were this company's latest financial results?

this company (2395.T) reported its latest results in an earnings disclosure filed with the Tokyo Stock Exchange. The full English translation is in the article above.

Where can I read this company's earnings disclosure in English?

Pulse News Wire provides real-time English translations of this company's TDNet filings, including this earnings report.

How quickly are this company's TSE filings translated into English?

Pulse News Wire translates Tokyo Stock Exchange disclosures typically within 5 minutes of filing, covering all 4,449 listed companies including this company.

| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.

This corporate disclosure from was processed by Pulse News Wire on February 6, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. Reports Q3 FY2026 Earnings Presentation

Source disclosure: February 06, 2026 SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. [2395.T] TOKYO, Feb 06 (Pulse News Wire) – SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395.T) released its earnings presentation for Q3 FY2026. Revenue was ¥222 million. Operating profit was ¥18 million. Net profit was ¥9 million. The equity ratio was 49.8%. For the full year, the company forecasts revenue of ¥222 million. Forecast operating profit is ¥18 million. Forecast net profit is ¥9 million. A

Source disclosure: February 06, 2026

SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. [2395.T]

TOKYO, Feb 06 (Pulse News Wire) – SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395.T) released its earnings presentation for Q3 FY2026.

The equity ratio was 49.8%.

Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.

AI-translated content. 🟢 Confidence: High See terms • Original filing

💬 Help us improve translation quality

Notice any errors in this article? Let us know with one click.

🎁 Report 3+ errors with your email and get a free month of premium access

About This Source

Pulse News Wire is a specialized financial intelligence platform dedicated to the translation and analysis of Tokyo Stock Exchange (TDNet) filings for global institutional investors. Every disclosure published on Pulse News Wire is derived directly from an official TDNet primary source document and processed typically within 5 minutes of filing using validated AI translation, providing cross-border investors with timely, structured access to Japanese corporate events.

What We Are Not

Pulse News Wire is a translation and distribution service for primary source documents. We do not provide investment advice, price targets, earnings estimates, or analyst commentary. Our articles reflect the content of the original filing and nothing more.

Pulse News Wire is not affiliated with, endorsed by, or in any way connected to the Tokyo Stock Exchange, Japan Exchange Group (JPX), TDNet, or any company whose disclosures appear on this site. We are an independent translation service. The companies we cover have not reviewed, approved, or contributed to any content published here.

SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. Reports Q3 FY2026 Earnings Presentation

Related Disclosures